espite the concerns about of cancer-related loss of appetite and weight among patients and their families, 1 cancer anorexia-cachexia syndrome (CACS) is underrecognized by medical providers and professional organizations. A recent review found that only 2.2% of guidelines -from 6 of 275 international oncological societies -provide physician recommendations for the management of CACS.
D
espite the concerns about of cancer-related loss of appetite and weight among patients and their families, 1 cancer anorexia-cachexia syndrome (CACS) is underrecognized by medical providers and professional organizations. A recent review found that only 2.2% of guidelines -from 6 of 275 international oncological societies -provide physician recommendations for the management of CACS. 2 Te seemingly low priority given to this condition also contrasts with many important advances in the feld, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic and supportive-care interventions. More than 900 scientifc papers have been published on CACS in the last 5 years, based on a PubMed search, and a new journal focusing on cachexia, sarcopenia, and muscle wasting was launched in 2010.
Furthermore, specialized clinics devoted to the management of CACS are a rarity, and when they do exist, they are in a few selected academic centers. [3] [4] [5] As such, oncologists and nurses likely are responsible for the initial assessment and management of most patients with this condition. A recent report from the Institute of Medicine drew atten-tion to the anticipated increase in palliative care burden as populations age and emphasized opportunities for interprofessional education and the integration of palliative care services into oncology practices. 6 However, in reality, time and resource limitations present challenging barriers for even the most basic assessment of nutritional or CACS symptom status in the busy clinical oncology practice.
Given those constraints, it is critical that oncologists are provided with brief, meaningful assessment tools to measure nutritional impact symptoms and other relevant CACS outcomes. Te American Society for Clinical Oncology's Quality Oncology Practice Initiative (QOPI) has adopted some individual symptom measures such as pain, constipation, and chemotherapy-induced nausea and vomiting but does not include specifc questions about appetite or other symptoms. 7 Te goals of the present study were to assess the attitudes of oncologists and nurses toward the detection and management of CACS, particularly in patients being treated for non-small-cell lung cancer (NSCLC), and to propose assessment techniques for CACS in daily oncology practice.
Methods and materials
From July 1, 2013-December 31, 2013, a series of 5 unique pilot surveys were undertaken. All of the questions were formulated by the authors of this paper and each survey was limited to 5 multiple-choice or open-response questions to encourage reply. Te surveys were administered electronically to a cross-section of US-based, self-identifed community medical oncologists and nurses from 30 different states and who had experience in the diagnosis and management of CACS in NSCLC patient populations.
Survey dissemination was directed to active members of the Sermo research database with the use of a proprietary MedPulse tool designed to achieve a random geographic distribution of respondents through a staged queryresponse process. Tis protocol sends small survey batches to a target list of health care providers and collects answers electronically. Subsequent batches are then directed to health care providers from geographic regions that are underrepresented in the accumulating database. Te process continues until the prespecifed number of complete responses has been collected and compiled. Response rates are not monitored with this technology. Te Sermo database for the United States comprises more than 275,000 active physicians, including 5,160 practicing oncologists and more than 150,000 specialty nursing health care providers, all of whom were invited to join and prequalifed through telephone or online screening before entering the database. Surveys 1-3 were directed at physicians and surveys 4 and 5 were directed at nurses (Table) . Surveys 1, 2, 4, and 5 were designed to gain insight into the recognition and monitoring of CACS, and Survey 3 focused on considerations around symptom management (see online material for the survey questions). In all, there were 151 respondents, including 101 oncologists and 50 nurses. Each respondent answered only one survey.
Results

Perceived frequency of CACS in NSCLC
When community oncologists were asked in Survey 1 about the likelihood of a patient with NSCLC developing CACS during therapy, 60% (15 of 25) indicated that this was inevitable or highly likely, and 4% (1 of 25) indicated that the likelihood was low (Figure 1 ). Te same community oncologists were asked about the likelihood of CACS developing in a patient who had completed a course of therapy and maintained good PS. In that scenario, most of the respondents indicated that CACS was somewhat less likely or unlikely to occur, and 4% (1 respondent) described CACS as very likely, and none thought it was inevitable.
Assessment and diagnosis
To understand current practices around the initial detection of CACS, we asked which personnel were most likely to identify the condition in patients with NSCLC (Survey 1). Sixty-nine percent of community oncologists (n = 25) identifed themselves as flling that role, and 15% said nurses flled the role. A small proportion (8%) indicated that CACS is identifed when chemotherapy doses are recalculated based on weight loss between ofce visits. In Survey 4, oncology nurses indicated that CACS is detected primarily by the practicing oncologist (32% of responses), the nurse practitioner/physician assistant (PA/NP; 28%), nursing staf (16%), or family members (16%). Likelihood that a patient with NSCLC will develop CACS CACS, cancer anorexia-cachexia syndrome; NSCLC, non-small-cell lung cancer FIGURE 2 Most important CACS-related diagnostic criteria or patient concern CACS, cancer anorexia-cachexia syndrome
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In Survey 3, most of the community oncologists (67%) identifed patient weight loss as the most important criterion for diagnosing CACS in daily practice. Tis was followed by muscle loss, poor appetite, low body mass index, and declining physical function ( Figure 2 ). Te same oncologists identifed declining physical function (41%) and poor appetite (24%) as the most important CACS-related concerns in patients and their families. Oncology nurses (Survey 4) relied on appetite loss reported either by the patient or a family member (84% of respondents) and weight loss (72%) to identify CACS, followed closely by diminished muscle strength (64%), quality of life (QoL) (64%), and activities of daily living (60%).
In Survey 3, the oncologists ranked the management of symptoms that afect appetite (ie, nausea, early satiety, pain, depression, constipation) Very Important (58.8% of respondents), Important (31.4%), or Somewhat Important (7.8%), with only 9.8% of respondents indicating current use of a formal tool to evaluate these symptoms. Just under half of the respondents (47%) reported they would consider incorporating a short (10-item) survey into their practice for ongoing patient assessment, and another 26% indicated that they would incorporate such a questionnaire depending on the usefulness of the information elicited. Eighteen percent indicated that they would not consider incorporating an instrument for this purpose.
In addition to clinical signs and symptoms, 94% of community oncologists indicated that albumin levels could provide additional insights into the assessment of weight loss. Levels of thyroid-stimulating hormone (TSH) and C-reactive protein (CRP) are used less often, by 19.6% and 13.7%, respectively.
Management strategies for CACS
In Survey 1, community oncologists identifed weight stabilization (56%) and improving tolerance for chemotherapy (20%) as important treatment goals. In Survey 2, the most common management strategies included nutritional intervention plus pharmacologic appetite stimulants (64%) or nutritional intervention plus pharmacologic appetite stimulants along with an exercise program (24%).
In Survey 4, 16% of oncology nurses indicated that internal cachexia management teams oversee CACS care in their practice settings, 8% said they refer patients to an external palliative care specialist, and 4% refer to an external nutritionist. In survey 5, nurses said that oversight responsibilities for supportive/palliative care fell to the oncologist (36%), a designated team within the practice (28%), or the collective eforts of physicians and staf (20%). Although no pharmacologic agent is approved currently for the treatment of CACS, most of the nurse respondents in Survey 4 described the initiation of drug management, either by the oncologist (48%) or NP/PA (32%) for patients with the condition.
Discussion
Te results of these pilot surveys provide insight into the detection and management of CACS by community oncology practitioners and underscore an urgent unmet need for standardized symptom assessment. An interesting perception of lower risk for CACS in NSCLC emerged for patients who maintain good PS during their and PS, as well as markers of infammation. 3, 12, 13 In research settings, laboratory assessment of serum albumin, CRP, TSH, vitamin D, and testosterone levels can ofer insight into the underlying mechanisms that may contribute to CACS.20 Te Glasgow Prognostic Score is a simple, objective, systemic infammation based approach using assessment of CRP and albumin levels 21 that has prognostic value independent of tumor stage, performance status, and treatment (active or palliative), in a variety of advanced common solid tumors. 22 Findings from preliminary studies have reported a high prevalence of vitamin D defciency in patients with cancer cachexia 23 and have shown that testosterone replacement improves some symptoms. 
Patient-reported outcomes
Te physician and patient concerns in this study (Figure 2 ) draw attention to the importance of incorporating patientreported outcome (PRO) assessments in routine clinical practice. Oncologists depend on patient-volunteered symptoms, however, without systematic inquiry, it is likely that symptoms such as anorexia are more prevalent than identifed by oncologists, because patients volunteer few symptoms relative to their total symptom experience. 10 Tere are currently no specifc questions about appetite in QOPI, or in some validated nutrition screening assessments such as the Malnutrition Universal Screening Tool (MUST). 25 A systematic review has found that even single-item symptom measures of appetite, fatigue, or pain are important indicators-separately or in combination-for survival. 26 Appetite scores also have been shown to provide important prognostic information independent of demographic (age, sex) and clinical variables (PS, distant metastases). 27 Although PROs increasingly are recognized as key outcomes, oncologists' views and attitudes about their clinical utility are important when considering the incorporation of assessment tools in daily practice. Recently, a small qualitative study found that oncologists are familiar with PROs and believe that symptoms such as poor appetite, depression, fatigue, insomnia, nausea, and pain are universal across cancer types and potentially could be measured by a single instrument. 28 Tere is no international consensus on the use of a tool for routine clinical assessment of PROs in CACS. 29 In North America, Europe, and Africa, the 10-item Edmonton Symptom Assessment Scale (ESAS) is used most frequently in palliative care practice and research. 30 In a standardized population-wide investigation, the ESAS detected a high prevalence of multiple symptoms in ambulatory cancer patients, similar to those reported in palliative care populations. 31 High symptom scores also precipitated clinical action on the part of health care providers. 32 Although the ESAS has the advantage of being able to assess symptom severity and includes appetite, it
Original Report frst course of treatment (Figure 1 ). However, fndings in a recent retrospective study of 425 patients found that a minority (40%) gained weight during concurrent chemoradiotherapy for stage III B NSCLC, and weight loss was associated with inferior survival. 8 Tere is also other evidence that various chemotherapies, 9 including cisplatinum, 10 can exacerbate muscle wasting. Weight loss is the core criterion for diagnosing CACS and is associated with a host of negative outcomes such as increased side-efect burden during chemotherapy and poor prognosis, 11 so the identifcation of nutritional impact symptoms such as nausea, depression, and constipation is important because they can be managed in many patients and result in improved oral intake and attenuate weight loss. 4 Te community oncologists who were surveyed reported considerable interest in adopting a brief symptom assessment tool to improve their ability to screen for afected or at-risk patients and to manage symptoms that negatively afect appetite. Teir key intervention goals for CACS included weight stabilization or gain and improved tolerance for chemotherapy.
Weight loss and laboratory parameters
Tis study confrms that weight loss is viewed as the most important clinical sign of CACS among health care providers. In general, the detection of CACS centers on evidence for involuntary weight loss. 3, 12, 13 A recent international consensus provides additional structure around the diagnosis and staging of CACS, recognizing that weight loss of more than 5% of baseline body weight over 6 months (or 2% when there is evidence of sarcopenia is present) is a key criterion for CACS. 12, 14, 15 An emphasis on total body weight or BMI also belies an insidious clinical challenge. Given the high prevalence of obesity in the general population, few patients are considered underweight at diagnosis, even if they have lost significant muscle mass. Indeed, at the time of diagnosis, when body composition is assessed by dual-energy x-ray absorptiometry scan or computed-tomography (CT) scan, many patients with NSCLC and an elevated BMI are found to be sarcopenic. Te condition, known as sarcopenic obesity, is a particularly poor prognostic indicator for various solid tumor types including NSCLC. 16 At least 50% of patients with cancer are older than 65 years of age, so sarcopenia of aging may compound the muscle loss related to CACS. Although CT imaging is emerging as a useful measure of body composition 17 and could infuence clinical decision making and chemotherapy dosing in future, 18, 19 quantifcation of lean body mass or fat is not yet conducted in daily clinical practice.
In addition to total body weight loss, recently developed staging criteria for the identifcation of pre-cachexia, cachexia and refractory cachexia, incorporate diminished caloric intake does not include other pertinent CACS symptoms such as constipation, early satiety, or dysgeusia. A more comprehensive evaluation of CACS would require an additional nutritional assessment measure such as the Patient-Generated Subjective Global Assessment (PG-SGA), a validated tool endorsed by the American Dietetic Society that identifes reversible factors contributing to poor oral intake (eg, nausea or severe from oral mucositis). 3, 33 More recently, a brief or abridged (a-PG-SGA) version of the PG-SGA was validated and shown to provide additional diagnostic and prognostic value in evaluating patients with cancer. 33 Te a-PG-SGA can be completed by patients in less than 5 minutes, and includes information about the severity and rate of weight loss, food intake, nutritional symptoms and functional status. Te a-PG-SGA also correlated with CACS features such as increased markers of infammation, higher severity of symptoms, decreased muscle strength, loss of fat mass, increased hospitalization, decreased chemotherapy tolerance and shorter life expectancy.
Te Mini Nutritional Assessment is simple, validated in the elderly, has independent prognostic value 34 and is relatively easy for a nontrained person to administer, but has lower specifcity for identifying malnutrition than the a-PG-SGA.
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Proposed standardized assessment Our survey results suggest that the identifcation and treatment of CACS may occur late in the disease trajectory, because most respondents described performing these tasks and referring to a palliative specialist team when they identifed uncontrolled symptoms. Such a delay could result in patients entering the late, refractory stage of cachexia and missing their anabolic opportunity to reverse muscle wasting and weight loss. In a recent study of 368 patients, fewer than 5% of patients gained skeletal muscle within 90 days of their deaths, based on body composition imaging using a CT scan. 36 Tis suggests that the window of anabolic potential and opportunity for intervention exists in the early phases of the disease trajectory. Given this result and the poor sensitivity and specifcity of physician and nurse evaluations of patient supportive care needs and symptoms, 37 the incorporation of a standard assessment system in clinical practice is essential.
A brief standardized assessment -including items that measure nutritional impact symptoms such as nausea, depression, and pain -should be extended to all oncology patients who are at risk for CACS. Tis would provide the opportunity to improve clinical care by identifying and managing symptoms that afect nutritional intake earlier in the CACS disease course. Te ESAS questions about appetite and fatigue would identify 2 of the cardinal symptoms of CACS along with other symptoms that could afect caloric intake, such as depression, nausea, and pain. Tis symptom assessment, along with a history of weight loss of 5% or more during the previous 6 months, would identify many patients with CACS. Finally, an additional nutritional assessment for these patients, such as the a-PG-SGA, could be easily implemented in oncology practices with sufcient personnel resources. Tus, some of the evaluations currently done in a specialized cachexia clinic could be adopted readily in daily oncological practice. A checklist of practice considerations involved in the evaluation and implementation of assessment tools is summarized in Figure 3 .
Multimodal management
Te implementation of standardized assessments has impor- 3 Essential considerations for CACS assessment in daily practice a a-PG-SGA, abridged Patient-Generated Subjective Global Assessment; CACS, Cancer AnorexiaCachexia Syndrome; ESAS, Edmonton Symptom Assessment Scale tant clinical implications. CACS responds, in part, to symptom management, 4 nutritional counseling, 38 and multimodality therapy 39 even though no single medication is approved for its treatment. Early-and late-phase trials of single agents such as ghrelin, 40 ghrelin mimetic/receptor agonists, 41 myostatin inhibitors, 42 and selective androgen-receptor modulators 43 have shown promise in improving clinical outcomes such as appetite, caloric intake, lean body mass, and physical function. Soon clinicians may have access to efective pharmacological agents that can be incorporated into a multimodal anticachexia strategy that includes symptom management, nutritional counseling, and exercise.
Study limitations
Several limitations should be considered when interpreting these study fndings. Tese include the use of a nonvalidated questionnaire; though one needs to bear in mind that there is no questionnaire available that would have met the objectives of this study. Te small number of respondents to each survey limits generalizability to all community practice settings, and given the limited number of questions per survey, we could not explore other barriers to the management of CACS.
Conclusions
Tis study suggests that community oncologists recognize the core criteria for the diagnosis of CACS, although the prevalence of this condition may be under recognized. Tere is considerable interest in adopting a brief symptom assessment tool for screening, management, and referral of afected or at-risk patients. A validated brief assessment tool could be incorporated into daily practice and accomplish the dual purpose of improved health care quality and early identifcation of patients with the CACS.
